Clinical trial
Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With…
NCT03481634 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT03481634 |
|---|---|
| Title | Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema |
| Official title | A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema |
| Acronym | KESTREL |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Macular Edema |
| Intervention type | Drug |
| Interventions | Brolucizumab, Aflibercept |
| Enrollment | 566 |
| Start date | Jul 23, 2018 |
| Primary completion | Nov 11, 2020 |
| Completion | Oct 18, 2021 |
| First posted | Mar 29, 2018 |
| Last update posted | Jan 30, 2023 |
| Countries | Argentina, Australia, Austria, Canada, Colombia, Israel, Italy, Japan, Netherlands, Portugal, Puerto Rico, Spain and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: